论文部分内容阅读
目的:检测卵巢上皮性癌组织中Seprase蛋白和mRNA的表达及预后意义。方法:分别采用免疫组化和原位杂交技术检测378例卵巢上皮性癌石蜡包埋组织中Seprase蛋白和86例组织mRNA的原位表达,12例正常卵巢组织作对照。结果:378例卵巢癌组织中,Seprase蛋白免疫组化阳性表达336例。12例正常卵巢组织中,Se-prase阳性4例。正常卵巢和卵巢癌组织中,Seprase蛋白阳性表达率分别为33.3%和88.9%,两组之间差异有统计学意义,χ2=32.12,P=0.001。Seprase蛋白的表达与卵巢癌组织学分级和类型及临床分期有关,而与患者年龄无关,与患者预后呈负关(P=0.033)。86例卵巢癌组织SeprasemRNA的表达阳性率为96.5%(83/86),显著高于其在正常卵巢组织的16.66%(2/12),P<0.01。SeprasemRNA和蛋白表达一致,rs=0.48,P=0.001。结论:Se-prase蛋白在卵巢癌的发生发展中起一定作用,并可能成为其预后因素。
Objective: To detect the expression of Seprase protein and mRNA in ovarian epithelial carcinoma and its prognostic significance. Methods: The expression of Seprase protein and 86 tissues in 378 cases of epithelial ovarian cancer tissues were detected by immunohistochemistry and in situ hybridization respectively. Twelve normal ovarian tissues were used as controls. Results: Among 378 cases of ovarian cancer, the positive expression of Seprase protein was 336 cases. In 12 cases of normal ovarian tissue, Se-prase positive in 4 cases. The positive rates of Seprase protein in normal ovarian and ovarian cancer tissues were 33.3% and 88.9%, respectively, with significant difference between the two groups (χ2 = 32.12, P = 0.001). The expression of Seprase protein was correlated with histological grade, type and clinical stage of ovarian cancer, but not with patient age, but negatively correlated with patient prognosis (P = 0.033). The positive expression rate of Seprase mRNA in 86 cases of ovarian cancer was 96.5% (83/86), which was significantly higher than that in normal ovarian tissue (2/12), P <0.01. The expression of Seprase mRNA and protein were consistent, rs = 0.48, P = 0.001. Conclusion: Se-prase protein plays a role in the development of ovarian cancer and may be the prognostic factor.